drugset / Trial / NCT02398591

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants

NCT02398591

Phase 1 Completed 24 enrolled Janssen Sciences Ireland UC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of three dosages (250, 500, and 1000 milligram \[mg\], or maximum tolerated dose \[MTD\]) of JNJ 53718678 when administered as single dose in fasting conditions in healthy Japanese adult participants in 3 cohorts.

Timeline

Start
2015-04-01
Primary completion
2015-07-15
Completion
2015-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilematovir Other / unclassified 250 mg Oral
Subject Rilematovir Other / unclassified 500 mg Oral
Subject Rilematovir Other / unclassified 1000 mg Oral

Indications

No indication recorded.